Bionics Institute
Kunal Rastogi is an experienced investment adviser and partner at Crestone Wealth Management, where Kunal has contributed since June 2016. With a strong background in wealth management, Kunal previously held positions at UBS Wealth Management, Macquarie Group, JBWere, and Deloitte Australia. Kunal's educational qualifications include a Master of Law and a Post Graduate Diploma of Tax Law from the University of Melbourne, as well as a combined degree in Law and Commerce from Monash University. Additionally, Kunal is actively involved in external engagement at the Bionics Institute and serves on the executive committee of the Old Wesley Collegians Association.
This person is not in any offices
Bionics Institute
The Bionics Institute is an internationally recognised, independent medical research institute that solves medical challenges with technology. We lead the world in the research and development of innovative medical devices and therapies to improve human health. Our multidisciplinary team is comprised of world-class scientists, engineers and researchers, and our laboratories are located in St Vincent’s Hospital Melbourne, close to our clinical collaborators. Together we transform the lives of people with a range of conditions, including Alzheimer’s disease, hearing impairment, vision loss, Crohnʼs disease, Parkinsonʼs disease, stroke, arthritis, incontinence and diabetes. The Bionics Institute has an impressive track record of translating medical device concepts into clinical reality dating back to 1986 when it was founded by Professor Graeme Clark, leader of the team that created Australiaʼs cochlear implant. Since then, Bionics Institute researchers have developed: • Australiaʼs first-generation bionic eye prototype implanted in clinical trials in 2018. - The epilepsy seizure monitoring device Minder™, commercialised through Epi-Minder Pty Ltd. - An adaptive deep brain stimulation system for Parkinsonʼs disease, commercialised through Deep Brain Stimulation Technologies Pty Ltd. - An innovative vagus nerve stimulation device to treat inflammatory bowel disease, which is moving into clinical trials and also being adapted to treat rheumatoid arthritis and diabetes. - Novel drug delivery methods for hearing loss; new diagnostic tools for improved diagnosis of infant hearing. Growth into new areas will build on our expertise in medical device development and a recent expansion of our world-class facilities to include the end-to-end medical device prototype manufacturing facility, Neo-Bionica.